Progyny’s share price has risen over the past year but is still down sharply over five years, which has left investors asking whether the current valuation around US$28.10 now fairly reflects the company’s prospects or still offers mispriced upside.

• Progyny’s share price has declined 39.1% over five years, which suggests long term holders are still in negative territory despite more recent gains.
• Future growth in fertility benefits adoption can support the valuation. However, any pressure on employer healthcare budgets or tightening benefits spending may weigh on what investors are willing to pay.
• Progyny is assessed as undervalued on 5 of 6 checks in our broader valuation work. This means the stock currently leans cheap on several measures even though headline multiples appear about right 5.

The issue now is whether Progyny’s current price already reflects this mixed track record and the more positive valuation checks or still leaves a margin of safety for new capital.

Does Progyny Look Fairly Valued on Earnings?

The P/E multiple fits Progyny well because it already generates positive earnings and investors often anchor on what they pay for each dollar of profit. At around 27.4x earnings, Progyny trades slightly above the broader Healthcare industry average of about 25.3x, yet sits well below the peer group average of roughly 41.1x.

The fair P/E ratio from the broader checks is around 27.9x, which is very close to the current market multiple. That tight gap suggests the market is broadly aligning Progyny’s share price with what the model indicates based on its profile, rather than applying a clear discount or premium. For you as an investor, the P/E alone therefore does not point to Progyny being obviously cheap or expensive at current levels.

On the P/E measure, Progyny’s stock currently looks priced at about a fair level rather than standing out as clearly undervalued or overvalued.

The Progyny Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Progyny pick up where the valuation puzzle leaves off and outline which growth, margin and earnings paths would need to occur for Progyny’s stock to be worth meaningfully more or less than today’s price. Instead of a single ratio or model output, they describe the future that number relies on so you can watch how Progyny’s actual progress lines up with those expectations on the Community page.

Community views on Progyny are split, with some investors seeing a meaningful valuation gap and others focusing on structural risks that could cap upside.

Bull case: 30% undervalued

"The newly established strategic presence with Amazon's Health Benefits Connector, along with data-driven partnerships such as Oura, could accelerate direct-to-member brand awareness and inbound enrollment, creating an outsized tailwind for top-line growth that is not yet reflected in consensus forecasts."

Bear case: 6% overvalued

"As efforts to curb healthcare costs intensify in the U.S., future policy actions could restrict employer funding or insurance coverage for fertility benefits, severely limiting Progyny's customer base and stalling revenue growth."

Do you think there's more to the story for Progyny? Head over to our Community to see what others are saying!

The Bottom Line

Progyny now sits in a zone where the P/E suggests the stock is priced about right rather than obviously mispriced. The broader valuation checks lean supportive of the shares, even though opinions differ on how much upside that leaves. The real swing factor from here is whether Progyny can sustain fertility benefits adoption and protect its economics if employer healthcare budgets tighten. Your decision comes down to whether the current multiple already reflects that risk or still leaves enough room for a positive surprise.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.